The Use of Anagrelide in Myeloproliferative Neoplasms, With Focus on Essential Thrombocythemia

Results of a recent study indicate that a combination of anagrelide with hydroxycarbamide or interferon is feasible and effective in patients with myeloproliferative neoplasms who have insufficient platelet response to monotherapy.

 Current Hematologic Malignancy Report

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.